

Arterielle Hypertonie – Neue Leitlinie der European Society of Hypertension 2023

V. Schwenger

1. GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 2020; 396: 1223–49
2. Mancia G et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH) and the European Renal Association (ERA). *J Hypertens* 2023; 41: 1874–2071
3. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. *Kidney Int* 2021; 99: S1–S87
4. Aggarwal R et al. Mortality Outcomes With Intensive Blood Pressure Targets in Chronic Kidney Disease Patients. *Hypertension* 2019; 73: 1275–82
5. Grams ME et al. Estimating time to ESRD using kidney failure risk equations: results from the African American Study of Kidney Disease and Hypertension (AASK). *Am J Kidney Dis* 2015; 65: 394–402
6. Klahr S et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. *N Engl J Med* 1994; 330: 877–84
7. Bidani AK, Griffin KA. Chronic kidney disease: bloodpressure targets in chronic kidney disease. *Nat Rev Nephrol* 2011; 7: 128–30
8. Ozemek C et al. Impact of therapeutic lifestyle changes in resistant hypertension. *Prog Cardiovasc Dis* 2020; 63: 4–9
9. Williamson JD et al. SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial. *JAMA* 2016; 315: 2673–82
10. Olde Engberink RHG et al. Effects of thiazidetype and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis. *Hypertension* 2015; 65: 1033–40
11. Roush GC et al. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. *Hypertension* 2015; 65: 1041–6
12. Ishani A et al. Diuretic Comparison Project Writing Group. Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events. *N Engl J Med* 2022; 387: 2401–10
13. Pedersen SA et al. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. *J Am Acad Dermatol* 2018; 78: 673–81.e9
14. Agarwal R et al. Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease. *N Engl J Med* 2021; 385: 2507–19
15. Carey RM et al.; American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; Stroke Council. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. *Hypertension* 2018; 72: e53–e90
16. Bhatt H et al. Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement. *J Am Soc Hypertens* 2016; 10: 493–9
17. Williams B et al.; British Hypertension Society’s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drugresistant

- hypertension (PATHWAY-2): a randomised, doubleblind, crossover trial. *Lancet* 2015; 386: 2059–68
18. Williams B et al.; British Hypertension Society programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study Group. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. *Lancet Diabetes Endocrinol* 2018; 6: 464–75
 19. Krieger EM et al.; ReHOT Investigators. Spironolactone Versus Clonidine as a Fourth-Drug Therapy for Resistant Hypertension: The ReHOT Randomized Study (Resistant Hypertension Optimal Treatment). *Hypertension* 2018; 71: 681–90
 20. Desai R et al. Comparative Safety and Effectiveness of Aldosterone Antagonists Versus Beta-Blockers as Fourth Agents in Patients With Apparent Resistant Hypertension. *Hypertension* 2022; 79: 2305–15
 21. Freeman MW et al.; BrigHTN Investigators. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. *N Engl J Med* 2023; 388: 395–405
 22. Bhatt DL et al. SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. *N Engl J Med* 2014; 370: 1393–1401
 23. Townsend RR et al. SPYRAL HTN-OFF MED trial investigators. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. *Lancet* 2017; 390: 2160–70
 24. Azizi M et al. RADIANCE-HTN Investigators. Endovascular ultrasound renal denervation to treat hypertension (RADIANCEHTNSOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. *Lancet* 2018; 391: 2335–45
 25. Kandzari DE et al. SPYRAL HTN-ON MED Trial Investigators. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. *Lancet* 2018; 391: 2346–55
 26. Azizi M et al. RADIANCE-HTN investigators. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. *Lancet* 2021; 397: 2476–86
-

Interventionelle Therapieoptionen venöser Erkrankungen

F. Linden, T. Mihu, R. Schell, N. Frey, C. Erbel

1. Ohlmeier C et al. [Estimating the incidence of venous thromboembolism (VTE) using various types of routine data of the German healthcare system]. *Z Evid Fortbild Qual Gesundhwes* 2018; 139: 46–52
2. Cohen AT et al. VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. *Thromb Haemost* 2007; 98: 756–64
3. Wendelboe AM, Raskob GE. Global Burden of Thrombosis: Epidemiologic Aspects. *Circ Res* 2016; 118: 1340–7
4. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. S3-Leitlinie Prophylaxe der venösen Thromboembolie (VTE). AWMF-Registernummer 003-001. Version 3.0 Stand 15.10.2015 (<https://register.awmf.org/de/leitlinien/detail/003-001>). Letzter Zugriff am 17.11.2022

5. Khan F et al. MARVELOUS Collaborators. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and metaanalysis. *BMJ* 2019; 366: l4363
6. Konstantinides SV et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). *Eur Heart J* 2020; 41: 543–603
7. Jiménez D et al. RIETE Investigators. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. *Arch Intern Med* 2010; 170: 1383–9
8. Meyer G et al. PEITHO Investigators. Fibrinolysis for patients with intermediate-risk pulmonary embolism. *N Engl J Med* 2014; 370: 1402–11
9. Kakkos SK et al. Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. *Eur J Vasc Endovasc Surg* 2021; 61: 9–82
10. Karathanos C et al. Efficacy of rivaroxaban in prevention of post-thrombotic syndrome: A systematic review and meta-analysis. *J Vasc Surg Venous Lymphat Disord* 2021; 9: 1568–76.e1
11. Baglin T. Prevention of post-thrombotic syndrome: a case for new oral anticoagulant drugs or for heparins? *J Thromb Haemost* 2012; 10: 1702–3
12. Galanaud JP, Kahn SR. The post-thrombotic syndrome: a 2012 therapeutic update. *Curr Treat Options Cardiovasc Med* 2013; 15: 153–63
13. Pillny M et al. Deep venous thrombosis during pregnancy and after delivery: indications for and results of thrombectomy. *J Vasc Surg* 2003; 37: 528–32
14. Kahn SR et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. *Ann Intern Med* 2008; 149: 698–707
15. Enden T et al. CaVenT Study Group. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. *Lancet* 2012; 379: 31–8
16. Vedantham S et al. ATTRACT Trial Investigators. Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis. *N Engl J Med* 2017; 377: 2240–52
17. Cohen JM, Akl EA, Kahn SR. Pharmacologic and compression therapies for postthrombotic syndrome: a systematic review of randomized controlled trials. *Chest* 2012; 141: 308–20
18. Kahn SR et al. The postthrombotic syndrome: evidencebased prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. *Circulation* 2014; 130: 1636–61
19. Sebastian T et al. Outcomes of endovascular reconstruction of the inferior vena cava with self-expanding nitinol stents. *J Vasc Surg Venous Lymphat Disord* 2018; 6: 312–20
20. Lichtenberg M, de Graaf R, Erbel C. Standards for recanalisation of chronic venous outflow obstructions. *Vasa* 2018; 47: 259–66
21. Oguzkurt L et al. Compression of the left common iliac vein in asymptomatic subjects and patients with left iliofemoral deep vein thrombosis. *J Vasc Interv Radiol* 2008; 19: 366–70
22. Richet MA. *Traite Pratique d'Anatomie Medico-Chirurgicale*. Paris: E. Chamerot Libraire Editeur; 1875
23. Kim HS et al. Embolotherapy for pelvic congestion syndrome: long-term results. *J Vasc Interv Radiol* 2006; 17: 289–97
24. Robinson JC. Chronic pelvic pain. *Curr Opin Obstet Gynecol* 1993; 5: 740–3
25. Soysal ME et al. A randomized controlled trial of goserelin and medroxyprogesterone acetate in the treatment of pelvic congestion. *Hum Reprod* 2001; 16: 931–9
26. Antignani PL et al. Diagnosis and treatment of pelvic congestion syndrome: UIP consensus document. *Int Angiol* 2019; 38: 265–83
27. Holdstock JM et al. Haemorrhoids are associated with internal iliac vein reflux in up to one-third of women presenting with varicose veins associated with pelvic vein reflux. *Phlebology* 2015; 30: 133–9

28. Gloviczki P et al. Society for Vascular Surgery; American Venous Forum. The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. *J Vasc Surg* 2011; 53(Suppl): 2S–48S
 29. Arnoldussen CWKP, de Wolf MAF, Wittens CHA. Diagnostic imaging of pelvic congestive syndrome. *Phlebology* 2015; 30(Suppl): 67–72
 30. Johnson D, Sandlow J. Treatment of varicoceles: techniques and outcomes. *Fertil Steril* 2017; 108: 378–84
 31. Goldstein M, Eid JF. Elevation of intratesticular and scrotal skin surface temperature in men with varicocele. *J Urol* 1989; 142: 743–5
 32. Clarke BG. Incidence of varicocele in normal men and among men of different ages. *JAMA* 1966; 198: 1121–2
 33. Abdulmaaboud MR et al. Treatment of varicocele: a comparative study of conventional open surgery, percutaneous retrograde sclerotherapy, and laparoscopy. *Urology* 1998; 52: 294–300
 34. Nabi G et al. Percutaneous embolization of varicoceles: outcomes and correlation of semen improvement with pregnancy. *Urology* 2004; 63: 359–63
-

Der ältere Patient in der Praxis: Bei Hypertonie und Herzinsuffizienz Biofaktorenmangel vermeiden

D. Birkelbach, K. Kisters, H.G. Classen

1. www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Gesundheit/Todesursachen/Tabellen/sterbefaelle-herz-kreislauf-erkrankungen-insgesamt.html
2. www.hochdruckliga.de/pressemitteilung/bluthochdruck-der-stille-saboteur-bundesweite-experten-sprechstunde-am-15-mai-zum-welthypertonietag-2024
3. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. *The Lancet* 2021; 398(10304): 957–80
4. Heseke H et al. ErnSTES-Studie, in DGE: Ernährungsbericht 2008, 157–204
5. D-A-CH Referenzwerte für die Nährstoffzufuhr 2015; 2. Auflage, 1. Ausgabe. <https://www.dge.de/wissenschaft/referenzwerte/>
6. www.gf-biofaktoren.de/tipps-tests/biofaktoren-raeuber/
7. Max Rubner-Institut (MRI): Nationale Verzehrstudie II. Ergebnisbericht, Teil 2. Karlsruhe 2008. https://www.mri.bund.de/fileadmin/MRI/Institute/EV/NVSII_Abschlussbericht_Teil_2.pdf, S. 123–4
8. Classen HG et al. Die Versorgung mit Magnesium in den kritischen Lebensphasen Kindheit und Ruhestand. *Nieren- und Hochdruckkrankheiten* 2024; 53: 270–7
9. Song Y et al. Dietary magnesium intake and risk of incident hypertension among middle-aged and older US women in a 10-year follow-up study. *Am J Cardiol* 2006; 98(12): 1616–21
10. Wannamethee SG et al. Serum magnesium and risk of incident heart failure in older men: The British Regional Heart Study. *Eur J Epidemiol* 2018; 33(9): 873–82
11. Kisters K et al. Ionized magnesium deficiency in elderly hypertensive patients – A pilot study. *Nutr Food Sci J* 2020; 3(2): 129–34

12. Verma H et al. Effect of magnesium supplementation on type 2 diabetes associated cardiovascular risk factors: A systematic review and meta-analysis. *J Hum Nutr Diet* 2017; 30(5): 621–33
13. Zhang X et al. Effects of magnesium supplementation on blood pressure. A meta-analysis of randomized double-blind placebo-controlled trials. *Hypertension* 2016; 68(2): 324–33
14. Cunha AR et al. Oral magnesium supplementation improves endothelial function and attenuates subclinical atherosclerosis in thiazide-treated hypertensive women. *J Hypertens* 2017; 35(1): 89–97
15. Kisters K. Oral magnesium supplementation improves borderline hypertension. *Magnes Res* 2011; 24(1): 17–8
16. Kisters K et al. Low ionized magnesium, vitamin D and interleukin 6 concentration in elderly hypertensive patients. *Trace Elem and Elektrolytes* 2021; 38(2): 63–7
17. Kisters K et al. Magnesiumhaushalt und -therapie bei Hypertonie. *Nieren- und Hochdruckkrankheiten* 2020; 49(5): 245–51
18. Iezzoni IG. Potassium and magnesium depletions in congestive heart failure--pathophysiology, consequences and replenishment. *Clin Calcium* 2005; 15(11): 123–33
19. Adamopoulos C et al. Low serum magnesium and cardiovascular mortality in chronic heart failure: a propensity-matched study. *Int J Cardiol* 2009; 136(3): 270–7
20. Rosanoff A et al. Recommendation on an updated standardization of serum magnesium reference ranges. *Eur J Nutr* 2022; 61(7): 3697–706
21. Micke et al. Serum magnesium: time for a standardized and evidence-based reference range. *Magnes Res* 2021; 34(2): 84–9
22. Nielsen FH. Dietary Magnesium and Chronic Disease. *Adv Chronic Kidney Dis* 2018; 25(3): 230–5
23. Micke O et al. Magnesium: Bedeutung für die hausärztliche Praxis – Positionspapier der Gesellschaft für Magnesium-Forschung e.V. *Dtsch Med Wochenschr* 2020; 145: 1628–34
24. Wang TJ et al. Vitamin D deficiency and risk of cardiovascular disease. *Circulation* 2008; 117(4): 503–11
25. Pilz S et al. Vitamin D status and arterial hypertension: a systematic review. *Nat Rev Cardiol* 2009; 6(10): 621–30
26. Pilz S et al. Role of vitamin D in arterial hypertension. *Expert Rev Cardiovasc Ther* 2010; 8(11): 1599–608
27. Holick MF et al. Vitamin D deficiency: a worldwide problem with health consequences. *Am J Clin Nutr* 2008; 87(4): 1080S–6S
28. Manson JE et al. Principal results of the VITamin D and Omega-3 Trial (VITAL) and updated meta-analyses of relevant vitamin D trials. *J Steroid Biochem Mol Biol* 2020; 198: 105522
29. Chandler PD et al. Effect of Vitamin D3 Supplements on Development of Advanced Cancer: A Secondary Analysis of the VITAL Randomized Clinical Trial. *JAMA Netw Open* 2020; 3(11): e2025850
30. Pilz S et al. Critical Appraisal of Large Vitamin D Randomized Controlled Trials. *Nutrients* 2022; 14(2): 303
31. Sutherland JP et al. Vitamin D Deficiency increases mortality risk in the OK Biobank. *Annals of Internal Medicine* 2022
32. Sluyter JD et al. Effect of Monthly, High-Dose, Long-Term Vitamin D Supplementation on Central Blood Pressure Parameters: A Randomized Controlled Trial Substudy. *J Am Heart Assoc* 2017; 6(10): e006802
33. Keum N et al. Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials. *Ann Oncol* 2019; 30(5): 733–43
34. Holick MF. Bioavailability of Vitamin D and its metabolites in black and white adults. *New England Journal of Medicine* 2013; 369(21): 2047–8
35. Pludowski P et al. Clinical Practice in the Prevention, Diagnosis and Treatment of Vitamin D Deficiency: A Central and Eastern European Expert Consensus Statement. *Nutrients* 2022; 14(7): 1483

36. Classen HG et al. Hypervitaminose D, Hyperkalzämie und die Rolle von Magnesium. *Nieren- und Hochdruckkrankheiten* 2022; 51(11): 446–51
37. Asif A, Farooq N. Vitamin D Toxicity. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing 2024 Jan. 2023 May 24
38. Pludowski P et al. Vitamin D Supplementation: A Review of the Evidence Arguing for a Daily Dose of 2000 International Units (50 microg) of Vitamin D for Adults in the General Population. *Nutrients* 2024; 16(3): 391
39. Zenuk C et al. Thiamine deficiency in congestive heart failure patients receiving long term furosemide therapy. *Can J Clin Pharmacol Winter* 2003; 10(4): 184–8
40. Jain A et al. Determining the Role of Thiamine Deficiency in Systolic Heart Failure: A Meta-Analysis and Systematic Review. *J Card Fail* 2015; 21(12): 1000–7
41. Katta N et al. Does Long-Term Furosemide Therapy Cause Thiamine Deficiency in Patients with Heart Failure? A Focused Review. *Am J Med* 2016; 129(7): 753.e7–e11
42. Schoenenberger AW et al. Thiamine supplementation in symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled, cross-over pilot study. *Clin Res Cardiol* 2012; 101(3): 159–64
43. DiNicolantonio J et al. Thiamine supplementation for the treatment of heart failure: a review of the literature. *Congest Heart Fail* 2013; 19(4): 214–22
44. Bozic I, Lavrnja I. Thiamine and benfotiamine: Focus on their therapeutic potential. *Heliyon* 2023; 9(11): e21839
45. www.gf-biofaktoren.de/diagnose/uebersicht-zur-labordiagnostik/
46. Pan X et al. Long-term cognitive improvement after Benfotiamine administration in patients with Alzheimer's Disease. *Neurosci Bull* 2016; 32(6): 591–6
47. Stracke H et al. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. *Exp Clin Endocrinol Diabetes* 2008; 116(10): 600–5